Prescription Only
This is an FDA-approved prescription product. It should only be obtained through licensed healthcare providers and pharmacies. Do not attempt to source through RUO or gray-market channels.
WADA S2
This substance falls under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you are subject to anti-doping rules, this category of substances is prohibited at all times.
Evidence visual
Tesamorelin evidence and risk matrix
advanced researcher fit
Evidence
Tier A
Risk
low
Regulatory
rx approved
WADA
S2
FDA
none
Route
subcutaneous
Higher-confidence evidence profile, but regulatory and sourcing checks still matter.
Overview
Tesamorelin is an FDA-approved GHRH analogue (brand name Egrifta/Egrifta WR) indicated for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Clinical endpoints commonly assessed at 26 weeks. Label warnings include increased risk of neoplasms, elevated IGF-1, fluid retention, glucose intolerance/diabetes, and hypersensitivity reactions. Contraindicated in active malignancy and pregnancy.
Decision path
Where Tesamorelin fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether Tesamorelin belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
GHRH analogue that increases GH and IGF-1 levels.
subcutaneous
FDA label: daily subcutaneous dosing (specific dose per formulation). Pivotal trials at 26 weeks.
Visceral fat reduction in HIV lipodystrophy (evidence-backed). General weight loss claims are limited.
Clinical endpoints assessed at 26 weeks in pivotal studies.
Active malignancy, pregnancy, pituitary gland disorders (per label).
Increased neoplasm risk, elevated IGF-1, fluid retention, glucose intolerance/diabetes, hypersensitivity.
CYP450-metabolized drugs; glucocorticoid replacement requirements may be affected.
Cost at a glance
Typical cycle cost
$600.00
Estimated monthly
$600.00
Protocol style
Continuous / ongoing
Continuous
Estimate confidence
High confidence
Assumes roughly 30 mg–60 mg per cycle, using 2 tracked affiliated listings.
Prescription-like use is better treated as ongoing therapy, so one pricing cycle equals one month.
Known Interactions
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for Tesamorelin.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.